Santhera Pharmaceuticals Holding AG (SPHDF) Q2 2026 Earnings Call Transcript

SA Transcripts 162.37K Followers Follow Santhera Pharmaceuticals Holding AG ( SPHDF ) Q2 2026 Earnings Call September 30, 2026 8:00 AM EDT Company Participants Catherine Isted - Chief Financial Officer Orlando Oliveira - Chief Executive Officer Shabir Hasham - Chief Medical Officer Presentation Operator Good afternoon, and welcome to the Santhera Pharmaceuticals Holdings AG Half Year Results Investor Presentation. [Operator Instructions] Before we begin, I'd like to submit the following poll. I'd now like to hand you over to the Santhera Pharmaceuticals Holdings team. Good afternoon. Catherine Isted Chief Financial Officer Good afternoon, and welcome to the first half results for the 6 months ending the 30th of June 2026. Giving the presentation today will be our new CEO, Orlando Oliveira; myself, Catherine Isted; and our Chief Medical Officer, Dr. Shabir Hasham. Can I please encourage you to type in questions into the Q&A box as we go along, and we will answer these at the end of the presentation. As always, we have a disclaimer. Please feel free to read this at your leisure. I now hand over to Orlando to go through the highlights of the first half of the year. Orlando Oliveira Chief Executive Officer Thank you very much, Catherine, and good afternoon, everyone. 2026 has been a strong year so far, and we have achieved a lot of success in terms of market access initiatives. I would like to take you through a few of our major achievements during the first 6 months. The first one, clearly, 4 out of the 5 major EU markets now are commercially launched. Pricing reimbursement has been secured in Spain and Italy. We continue strong commercial momentum in Germany with volumes up 50% in the first half of '26 versus the first half of '25. In the U.K., we're up 40% in Q2 '26 versus Q1 '26. Our strategic APAC licensing agreement signed with Nxera has been a key achievement as well. This licensing, to remind everyone, is focused on Japan, South